Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

0 new patients are infected each year. It is estimated that 10,000 to 12,000 patients die annually in the United States from complications resulting from HCV infection. The current standard of care for treating chronic hepatitis C is combination therapy consisting of pegylated alpha interferon and ribavirin.

About Diabetes

Diabetes affects more than 20 million in the United States and an estimated 194 million adults worldwide. Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States. According to the U.S. Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve target A1c levels with their current treatment regimen.

DUROS is a registered trademark of ALZA Corporation (Mountain View, CA) licensed to Intarcia Therapeutics, Inc. Intarcia and its logo are trademarks of Intarcia Therapeutics, Inc. (Emeryville, CA).

CONTACT: James Ahlers, Chief Financial Officer of Intarcia Therapeutics,+1-510-652-2600, ext 235

Web site: http://www.intarcia.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:7/31/2014)... -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), ... Pump, today reported its financial results for the quarter ended ... quarter of 2014 to the same period of 2013: ... million , t:slim Pump shipments grew 64 percent to ... months ended June 30, 2014 to the same period of ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Cepheid to Webcast Upcoming Financial Presentations 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3
... III Study Provides Further Evidence of,the Significant ... Treatment,of Rheumatoid Arthritis, BASEL, Switzerland, June 6, ... multinational phase III Actemra,(tocilizumab) study, successfully reached ... proportion of patients treated with Actemra,in combination ...
... Topical Therapy Reduces TNF-alpha Production Through Inhibition,of ... 2007 /PRNewswire/ -- Anacor,Pharmaceuticals, a privately held ... placebo-controlled Phase 1 trial of,AN2728, a first-in-class ... psoriasis. The trial showed AN2728 to be,well-tolerated, ...
Cached Medicine Technology:New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 Etymotic ... announced a new sponsorship of the DrumLine Battle® ... are Etymotic’s hearing protection products ETY•Plugs® and Music•PRO® ... against the harmful effects of high-level sound. Etymotic ... sponsorship at the Drum Corps International Championships on ...
(Date:7/31/2014)... black women put concerns about their hair above their ... the U.S. Centers for Disease Control and Prevention that ... States are overweight or obese. Yet some of them ... their hair restyled or restraightened, the University of Colorado ... also noted a shift toward more "low-maintenance" hairstyles, which ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Rich Dad® ... charity yard sale to benefit Habitat for Humanity. The yard ... was raised with 100% of the proceeds donated to Habitat ... items not sold at the event were donated to the ... Road, North Fort Myers, Florida 33903. , Of the ...
(Date:7/31/2014)... aimed to diagnose pediatric patients with suspected appendicitis ... without affecting diagnostic accuracy, Mayo Clinic Children,s Center ... in the journal Surgery . , Acute ... abdominal pain in children. Appendicitis occurs when the ... scans are often used to diagnose acute appendicitis ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Insight Accelerator ... a Series A round of investment for $4.6 million ... device for collecting vital signs. The company joined ... technology to fruition with the help of Insight development ... our reason for launching the Accelerator,” says Steve McPhilliamy, ...
Breaking Medicine News(10 mins):Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2Health News:Hairdo Trumps Exercise for Many Black Women, Study Finds 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3
... rats finds that even one injection leads to dependent ... naturally occurring protein plays a role in the disrupted ... with drug and alcohol dependence, says a new study. ... changes in association with drug abuse, it could potentially ...
... May 28 (HealthDay News) --Should it worry you that there ... , Not especially, when you consider that there are 44 ... , This information comes to you from scientists at the ... same techniques that enabled them to map the human genetic ...
... Controlling Weight before PregnancyWHITE PLAINS, N.Y., May 28 ... right amount during pregnancy is critical to giving a ... Dimes said today in response to new guidelines from ... issued new guidelines for the amount of weight a ...
... Logistics (NGL), a premier provider of mission critical transportation, service/spare parts ... network of forward stocking locations (FSL,s). , ... Broomfield, ... provider of mission critical transportation, service/spare parts logistics , and ...
... Perot Systems, RCS advantages of increased cash flows and ... providersPLANO, Texas, May 28 Amerinet, a leading national ... PER ) ( www.perotsystems.com ) ... Systems revenue cycle solutions available to Amerinet,s acute and ...
... Patent Covers High-throughput, Anchorage-independent Assay for Screening Compounds ... Falcon Genomics, Inc. announced today that it ... covering the Company,s Cancer BioChip System (CBCS) for ... in a high-throughput in vitro setting ...
Cached Medicine News:Health News:Study Finds Multitude of Bacteria on Human Skin 2Health News:Study Finds Multitude of Bacteria on Human Skin 3Health News:New Guidelines to Fight Obesity in Pregnancy Issued 2Health News:New Guidelines to Fight Obesity in Pregnancy Issued 3Health News:NGL Expands Global Network to Service Parts Logistics Customers 2Health News:NGL Expands Global Network to Service Parts Logistics Customers 3Health News:Perot Systems to Supply Revenue Cycle Solutions to Amerinet Members Nationwide 2Health News:Perot Systems to Supply Revenue Cycle Solutions to Amerinet Members Nationwide 3Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2
... a ubiquitous enzyme that catalyzes the ... also the specific protein that is ... (EMA) tests (Bio-Rad catalog number 29003 ... tests are highly sensitive and specific ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: